Author:
Martinez Marilyn N.,Fahmy Raafat
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Bermingham E, Del Castillo JR, Lainesse C, Pasloske K, Radecki S. Demonstrating bioequivalence using clinical endpoint studies. J Vet Pharmacol Ther. 2012;35 Suppl 1:31–7.
2. FDA Guidance for Industry. 2008. Waivers of in vivo animal drugs in soluble powder oral dosage form products and Type A medicated articles. Guidance #171. http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM052493.pdf. Accessed 18 Nov 2014.
3. Chang RK, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatological products. AAPS J. 2013;15(1):41–52.
4. Fahmy R, Danielson D, Martinez MN. Quality by design and the development of solid oral dosage forms. In: Rathbone MJ, McDowell A, editors. Long acting animal health drug products: fundamentals and applications. New York: Springer; 2013. p. 107–30.
5. Rahman Z, Xu X, Katragadda U, Krishnaiah YS, Yu L, Khan MA. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion. Mol Pharm. 2014;11:787–99.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献